Munich Cancer Registry

- Survival
- Selection Matrix
- Homepage

Munich Cancer Registry at Munich Cancer Center
Marchioninistr. 15
Munich, 81377
Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Baseline statistics

C30, C31: Nasal cavity, middle ear, sinuses cancer

Year of diagnosis	1998-2012
Patients	485
Diseases	488
Creation date	03/20/2014
Export date	02/12/2014
Population	4.5 m

http://www.tumorregister-muenchen.de/en/facts/base/base_C3031E.pdf

Global Statements about the statistics on the Internet − Baseline Statistics (grey button), Survival (red button)

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut[#], with a total of 4.5 million inhabitants, account for the frequency of cancer diseases[##] and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases[###] are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.

The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR. The time-delayed acquisition of data and the occasionally high DCO-rates indicate optimizing reserves, among others, because of current financial and legal conditions that hinder the analyses.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to tumor@ibe.med.uni-muenchen.de.

Munich Cancer Registry, March 2014

[#] Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.51 million to 3.96 in 2002, and to 4.52 million in 2007). Death certificates from 2013 are incorporated into these analyses.

[##] Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.

[###] DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate. A high proportion of DCO cases (≥5%) in particular cancer types indicate insufficient participation of specific cancer specializations.

Some remarks regarding this cancer type

As a general rule, these few results from the TRM form the basis of sophisticated analyses. For head and neck tumors this is not the case. Therefore the results for head and neck tumors should be interpreted with caution. In part this is due to problems of classification because of limited specific details of locality. Additionally, with advanced tumors in a close topographic location it is often not possible to determine the exact ICD localization of a tumor.

ICD-10 codes used for specifying cancer site

ICD-10	Description
C30.-	Malignant neoplasm of nasal cavity and middle ear
C30.0	Nasal cavity
C30.1	Middle ear
C31.-	Malignant neoplasm of accessory sinuses
C31.0	Maxillary sinus
C31.1	Ethmoidal sinus
C31.2	Frontal sinus
C31.3	Sphenoidal sinus
C31.8	Overlapping lesion of accessory sinuses
C31.9	Accessory sinus, unspecified

INCIDENCE

Table 1

Patient cohorts by year of diagnosis including DCO cases and multiple primaries, and with proportion of deaths and active follow-up

Year of diagnosis	Cases n	DCO cases n	Prop. DCO %	Prop. mult. primaries %	Prop. deaths %	Prop. actively followed %	
1998	21	1	4.8	33.3	81.0	95.2	
1999	18			44.4	72.2	100.0	
2000	20	1	5.0	20.0	70.0	100.0	
2001	13	1	7.7	23.1	76.9	100.0	
2002	25	2	8.0	28.0	76.0	100.0	#
2003	37	2	5.4	35.1	75.7	97.3	#
2004	23			34.8	47.8	100.0	#
2005	31			32.3	74.2	100.0	#
2006	39	3	7.7	33.3	66.7	100.0	#
2007	44	3	6.8	29.5	38.6	84.1	# ##
2008	40	2	5.0	25.0	45.0	72.5	
2009	44			25.0	36.4	77.3	
2010	51	1	2.0	19.6	25.5	76.5	
2011	46	2	4.3	32.6	41.3	69.6	
2012	36	1	2.8	30.6	16.7	100.0	###
1998-2012	488	19	3.9	29.3	51.2	88.5	

The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

Since 2007 the percentage of actively followed patients sharply declined compared to the previous years. This is a consequence of ambiguous data protection rules that currently forbid cancer registries in Bavaria to obtain the essential life status informations from competent registration offices.

Please be aware that data of recent annual patient cohorts may not yet be fully processed. Therefore, the presented figures and tables are potentially related to different time periods as pointed out in the respective headlines or legends.

Table 1a

Patient cohorts by year of diagnosis and gender
including DCO cases

Year of diagnosis	All n	Males n	Females n	Prop. males %
1998	21	15	6	71.4
1999	18	11	7	61.1
2000	20	15	5	75.0
2001	13	8	5	61.5
2002	25	14	11	56.0
2003	37	22	15	59.5
2004	23	15	8	65.2
2005	31	20	11	64.5
2006	39	21	18	53.8
2007	44	30	14	68.2
2008	40	28	12	70.0
2009	44	26	18	59.1
2010	51	34	17	66.7
2011	46	33	13	71.7
2012	36	18	18	50.0
1998-2012	488	310	178	63.5

Table 2

Incidence measures by year of diagnosis and gender including DCO cases
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.52 m as of 2007, respectively)

Year of diagnosis	Males n	Females n	Males Inc. raw	Fem. Inc. raw	Males Inc. WS	Fem. Inc. WS	Males Inc. ES	Fem. Inc. ES	Males Inc. BRD-S	Fem. Inc. BRD-S
1998	15	6	1.4	0.5	0.8	0.3	1.2	0.4	1.7	0.5
1999	11	7	1.0	0.6	0.6	0.2	0.8	0.3	0.9	0.6
2000	15	5	1.3	0.4	0.8	0.2	1.2	0.3	1.5	0.3
2001	8	5	0.7	0.4	0.4	0.2	0.6	0.2	0.9	0.3
2002	14	11	0.8	0.6	0.4	0.3	0.6	0.4	0.8	0.5
2003	22	15	1.2	0.8	0.7	0.4	1.0	0.5	1.2	0.7
2004	15	8	0.8	0.4	0.5	0.2	0.7	0.3	0.9	0.3
2005	20	11	1.1	0.6	0.6	0.2	0.8	0.3	1.0	0.4
2006	21	18	1.1	0.9	0.7	0.5	0.9	0.6	1.1	0.8
2007	30	14	1.4	0.6	0.8	0.3	1.1	0.4	1.4	0.5
2008	28	12	1.3	0.5	0.8	0.3	1.0	0.4	1.1	0.4
2009	26	18	1.2	0.8	0.7	0.4	1.0	0.5	1.2	0.6
2010	34	17	1.5	0.7	0.9	0.3	1.2	0.4	1.4	0.5
2011	33	13	1.4	0.6	0.8	0.3	1.1	0.4	1.3	0.5
2012	18	18	0.8	0.8	0.5	0.4	0.6	0.5	0.7	0.6
1998-2012	310	178	1.1	0.6	0.7	0.3	0.9	0.4	1.1	0.5

The computation of the incidence measures includes all primaries, irrespective of first or subsequent malignancy.

Table 3

Age distribution parameters by year of diagnosis (All)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	21	66.3	12.4	38.0	84.5	53.1	62.1	67.1	74.9	80.4
1999	18	63.9	15.0	33.5	82.4	36.0	59.3	66.5	75.8	80.9
2000	20	65.7	16.4	20.4	90.5	46.9	58.3	67.2	74.5	86.6
2001	13	66.9	18.0	37.4	89.9	44.6	53.0	66.8	83.6	84.7
2002	25	67.8	12.8	41.3	92.7	51.7	61.1	66.1	77.9	83.3
2003	37	65.2	16.3	16.2	91.8	46.1	52.5	67.3	78.9	84.2
2004	23	65.5	15.3	25.9	88.6	46.5	58.3	65.3	78.9	82.7
2005	31	68.6	15.3	31.7	96.1	44.7	58.3	71.1	78.1	83.7
2006	39	64.9	13.4	24.1	91.0	48.9	54.0	64.8	75.1	81.3
2007	44	63.0	16.0	20.2	86.2	39.0	54.0	64.9	77.5	81.4
2008	40	61.5	18.9	14.1	93.9	38.5	46.3	62.6	72.1	90.5
2009	44	64.2	17.8	2.4	90.1	41.2	52.6	67.0	77.7	83.8
2010	51	65.7	17.3	16.6	103	44.9	56.3	69.3	76.7	85.5
2011	46	63.8	14.2	37.7	85.4	46.4	51.6	65.3	76.9	79.4
2012	36	63.7	15.2	18.6	92.5	43.3	55.4	63.5	72.2	84.3
1998-2012	488	64.8	15.7	2.4	103	44.0	54.5	66.4	76.8	83.6

Table 3a

Age distribution parameters by year of diagnosis (MALES)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	15	65.4	14.1	38.0	84.5	38.2	58.4	66.8	75.4	82.7
1999	11	56.2	14.1	33.5	72.8	36.0	38.6	60.7	66.3	70.3
2000	15	64.0	16.2	20.4	85.5	44.1	58.0	68.8	73.7	84.2
2001	8	66.7	14.9	51.5	84.7	51.5	53.8	61.7	83.4	84.7
2002	14	69.1	14.7	41.3	92.7	46.6	61.1	69.4	80.8	85.8
2003	22	63.0	13.7	38.2	87.0	46.1	49.8	64.2	71.1	79.6
2004	15	63.3	16.2	25.9	83.4	43.0	54.4	63.3	77.3	82.7
2005	20	63.4	14.1	31.7	78.8	42.5	54.7	68.2	75.2	77.8
2006	21	62.7	11.5	44.8	86.9	48.9	54.0	63.8	68.8	76.9
2007	30	61.6	17.2	20.2	86.2	37.5	53.6	62.0	77.8	81.8
2008	28	58.9	16.1	35.5	93.9	37.9	44.7	59.6	69.5	79.3
2009	26	61.8	19.5	2.4	86.8	39.0	46.8	64.9	77.4	82.0
2010	34	61.7	17.2	16.6	91.3	37.6	51.8	65.6	71.9	76.8
2011	33	64.0	14.2	37.7	85.4	44.1	53.4	64.6	76.3	79.0
2012	18	59.8	15.9	18.6	84.3	40.8	52.3	61.4	71.6	78.4
1998-2012	310	62.5	15.5	2.4	93.9	40.9	53.0	64.3	74.4	81.1

Table 3b

Age distribution parameters by year of diagnosis (FEMALES)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	6	68.6	6.7	58.1	76.2	58.1	64.4	69.0	74.9	76.2
1999	7	76.0	5.1	66.8	82.4	66.8	73.4	76.2	80.9	82.4
2000	5	70.5	17.9	49.6	90.5	49.6	59.3	65.6	87.7	90.5
2001	5	67.0	24.2	37.4	89.9	37.4	44.6	79.5	83.8	89.9
2002	11	66.0	10.3	51.7	83.3	53.9	55.5	66.1	77.7	77.9
2003	15	68.3	19.6	16.2	91.8	48.0	52.5	75.2	80.1	84.2
2004	8	69.6	13.7	47.3	88.6	47.3	60.1	69.8	80.7	88.6
2005	11	78.2	12.9	57.9	96.1	58.3	69.9	80.4	89.8	94.1
2006	18	67.5	15.2	24.1	91.0	49.9	63.7	70.5	77.1	83.4
2007	14	66.1	13.2	39.0	83.6	47.7	62.6	67.9	77.1	79.1
2008	12	67.6	23.9	14.1	93.0	44.6	55.7	66.4	90.5	91.7
2009	18	67.6	14.7	41.2	90.1	49.9	54.5	71.2	79.9	85.8
2010	17	73.8	14.9	52.1	103	55.2	58.8	75.7	85.5	89.7
2011	13	63.4	14.8	46.4	81.1	46.7	48.9	66.0	77.1	79.4
2012	18	67.5	13.9	42.5	92.5	43.3	60.2	66.1	77.2	88.4
1998-2012	178	68.9	15.3	14.1	103	48.9	58.8	70.2	79.9	88.3

Table 4

Age distribution by 5-year age group and gender for period 1998-2012 (incl. DCO)

Age at diagnosis Years	Cases n	%	Cum.%	Males n	%	Cum.%	Females n	%	Cum.%
0-4	1	0.2	0.2	1	0.3	0.3			0.0
5-9	0	0.0	0.2			0.3			0.0
10-14	1	0.2	0.4			0.3	1	0.6	0.6
15-19	4	0.8	1.2	3	1.0	1.3	1	0.6	1.1
20-24	3	0.6	1.8	2	0.6	1.9	1	0.6	1.7
25-29	1	0.2	2.0	1	0.3	2.3			1.7
30-34	4	0.8	2.9	4	1.3	3.5			1.7
35-39	18	3.7	6.6	16	5.2	8.7	2	1.1	2.8
40-44	26	5.3	11.9	21	6.8	15.5	5	2.8	5.6
45-49	32	6.6	18.4	19	6.1	21.6	13	7.3	12.9
50-54	36	7.4	25.8	26	8.4	30.0	10	5.6	18.5
55-59	47	9.6	35.5	30	9.7	39.7	17	9.6	28.1
60-64	54	11.1	46.5	39	12.6	52.3	15	8.4	36.5
65-69	57	11.7	58.2	35	11.3	63.5	22	12.4	48.9
70-74	61	12.5	70.7	41	13.2	76.8	20	11.2	60.1
75-79	65	13.3	84.0	37	11.9	88.7	28	15.7	75.8
80-84	42	8.6	92.6	22	7.1	95.8	20	11.2	87.1
85+	36	7.4	100.0	13	4.2	100.0	23	12.9	100.0
All ages	488	100.0		310	100.0		178	100.0	

Included in the statistics are 39.0% multiple primaries in males and 36.2% in females.

Table 5

Age-specific incidence, DCO rate and proportion of all cancers
for period 1998-2012

Age at diagnosis Years	Males n	Females n	Males Age-spec. incid.	Females Age-spec. incid.	Males DCO rate n=11 %	Females DCO rate n=8 %	Males Prop.all cancers n=146755 %	Females Prop.all cancers n=142297 %
0- 4	1		0.1	0.0			0.3	
5- 9			0.0	0.0				
10-14		1	0.0	0.1				0.6
15-19	3	1	0.2	0.1			0.9	0.4
20-24	2	1	0.1	0.1			0.4	0.2
25-29	1		0.1	0.0			0.1	
30-34	4		0.2	0.0			0.3	
35-39	16	2	0.7	0.1			0.8	0.1
40-44	21	5	0.9	0.2			0.7	0.1
45-49	19	13	0.9	0.6		7.7	0.4	0.2
50-54	26	10	1.4	0.5			0.3	0.1
55-59	30	17	1.8	1.0		5.9	0.2	0.1
60-64	39	15	2.4	0.9			0.2	0.1
65-69	35	22	2.4	1.4	5.7	9.1	0.1	0.1
70-74	41	20	3.5	1.5	2.4		0.2	0.1
75-79	37	28	4.9	2.6	5.4		0.2	0.2
80-84	22	20	4.8	2.3	9.1		0.2	0.1
85+	13	23	4.2	2.8	30.8	17.4	0.1	0.1
All ages	310	178			3.5	4.5	0.2	0.1
Incidence								
Raw			1.1	0.6				
WS			0.7	0.3				
ES			0.9	0.4				
BRD-S			1.1	0.5				

The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).

Table 6a

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of second primaries for period 1998-2012
MALES

Diagnosis		Observed n	Expected n	SIR	LCL 95%	UCL 95%		EAR	DCO %
C00	Lip	2	0.0	178.2	21.6	643.8	#	29.7	
C03-C06	Oral cavity	3	0.1	33.7	7.0	98.5	#	43.4	
C15	Oesophagus	2	0.2	11.2	1.4	40.3	#	27.2	
C16	Stomach	3	0.4	7.0	1.4	20.4	#	38.3	
C18	Colon	3	1.0	3.0	0.6	8.7		29.7	
C30-C31	Sinuses	2	0.0	112.1	13.6	404.9	#	29.6	50.0
C33-C34	Lung	3	1.2	2.5	0.5	7.3		26.7	
C43	Malign. melanoma	2	0.4	5.0	0.6	18.0		23.9	100.0
C82-C85	NHL	2	0.4	5.0	0.6	18.1		23.9	
C91-C96	Leukaemia	2	0.2	12.2	1.5	44.1	#	27.4	
Other primaries		12	4.5	2.7	1.4	4.7	#	111.8	
Not observed		0	1.9	0.0	0.0	2.0		-28.2	
All mult. primaries		36	10.3	3.5	2.4	4.8	#	383.4	8.3

Patients	203
Mean age at second malignancy (years)	71.8
Person-years	670
Mean observation time (years)	3.3
Median observation time (years)	2.3

The occurrence of second malignancy is statistically significant.

Observed second primaries with count 1 are pooled in category "Other primaries".

Table 6b

Standardized incidence ratio (SIR, with 95% confidence limits),
excess absolute risk (EAR) and DCO rate of second primaries
for period 1998-2012
FEMALES

Diagnosis	Observed n	Expected n	SIR	LCL 95%	UCL 95%	EAR	DCO %
C91-C96 Leukaemia	2	0.1	24.3	2.9	87.6 #	47.0	
Other primaries	8	1.7	4.8	2.1	9.4 #	155.1	25.0
Not observed	0	3.2	0.0	0.0	1.2	-77.6	
All mult. primaries	10	4.9	2.0	1.0	3.7	124.4	20.0

Patients	127
Mean age at second malignancy (years)	66.9
Person-years	408
Mean observation time (years)	3.2
Median observation time (years)	1.8

The occurrence of second malignancy is statistically significant.

Observed second malignancies with count 1 are pooled in category "Other primaries".



Figure 7. Age distribution and age-specific incidence



Figure 7a. Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).

Reference:

Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data, released April 2012, based on the November 2011 submission. http://www.seer.cancer.gov.



Figure 8. Cumulative follow-up years depending on time since diagnosis

The increase of the lost to follow-up rate can be interpreted as a consequence of a declining number of survivors over time.

Average incidence (world standard population) 2003 - 2008: Males



Average incidence (world standard population) 2003 - 2008: Females



Figure 9a. Map of cancer incidence (world standard population, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual incidence rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 0.7/100,000 WS N=127, females 0.3/100,000 WS N=77). Since cancer data are not available in some counties until 2007, the local incidence rates were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 4 women were identified with newly diagnosed nasal cavity, middle ear, sinuses cancer. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 0.5/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.1 and 2.0/100,000.

Standardized incidence ratio (SIR) 2003 - 2008: Males



Standardized incidence ratio (SIR) 2003 - 2008: Females



Figure 9b. Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual SIR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=127, females N=77). Since cancer data are not available in some counties until 2007, the local SIR values were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 4 women were identified with newly diagnosed nasal cavity, middle ear, sinuses cancer. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 1.77. Though, the value of this parameter may vary with an underlying probability of 99% between 0.30 and 5.57, and is therefore not statistically striking.

MORTALITY

Table 10a

Patient cohorts of incident cancers by year of diagnosis, follow-up status, proportion of DCO, deaths among the annual cohorts, and proportion of available death certificates (with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.52 m as of 2007, respectively)

Year of diagnosis	Incident cases n	Prop. actively followed %	Prop. DCO %	Deaths n	Prop. deaths %	Prop. deaths with death certific. %
1998	21	95.2	4.8	17	81.0	94.1
1999	18	100.0		13	72.2	92.3
2000	20	100.0	5.0	14	70.0	100.0
2001	13	100.0	7.7	10	76.9	100.0
2002	25	100.0	8.0	19	76.0	94.7
2003	37	97.3	5.4	28	75.7	96.4
2004	23	100.0		11	47.8	100.0
2005	31	100.0		23	74.2	100.0
2006	39	100.0	7.7	26	66.7	100.0
2007	44	84.1	6.8	17	38.6	100.0
2008	40	72.5	5.0	18	45.0	100.0
2009	44	77.3		16	36.4	100.0
2010	51	76.5	2.0	13	25.5	100.0
2011	46	69.6	4.3	19	41.3	94.7
2012	36	100.0	2.8	6	16.7	100.0
1998-2012	488	88.5	3.9	250	51.2	98.0

Table 10b

Annual cohorts of incident cancers and deaths, proportion of death certificates and cases deceased the same year of cancer diagnosis
(incl. DCO)
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.52 m as of 2007, respectively)

Year of diagnosis/ death	Incident cases n	Deaths n	Prop. deaths with death certific. %	Deaths in same year n	Prop. deaths in same year %
1998	21	12	83.3	3	14.3
1999	18	9	77.8	2	11.1
2000	20	20	100.0	1	5.0
2001	13	16	93.8	3	23.1
2002	25	20	100.0	3	12.0
2003	37	24	100.0	7	18.9
2004	23	21	90.5	1	4.3
2005	31	25	96.0	5	16.1
2006	39	29	100.0	6	15.4
2007	44	22	95.5	7	15.9
2008	40	25	100.0	7	17.5
2009	44	22	100.0	1	2.3
2010	51	27	100.0	2	3.9
2011	46	28	96.4	5	10.9
2012	36	30	96.7	2	5.6
1998-2012	488	330	96.7	55	11.3

Table 10c

Annual cohorts of deaths, proportion of cancer-related and not cancer-related deaths, and cancer recorded on death certificates (incl. DCO)
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.52 m as of 2007, respectively)

Year of death	Deaths n	Prop. cancer-related %	Prop. not cancer-related %	Prop. cancer recorded on death certificate %
1998	12	58.3	41.7	90.0
1999	9	55.6	44.4	100.0
2000	20	85.0	15.0	85.0
2001	16	75.0	25.0	100.0
2002	20	50.0	50.0	70.0
2003	24	70.8	29.2	79.2
2004	21	57.1	42.9	68.4
2005	25	84.0	16.0	91.7
2006	29	82.8	17.2	82.8
2007	22	77.3	22.7	90.5
2008	25	76.0	24.0	84.0
2009	22	77.3	22.7	95.5
2010	27	66.7	33.3	77.8
2011	28	75.0	25.0	81.5
2012	30	63.3	36.7	72.4
1998-2012	330	71.5	28.5	83.1

Table 11a

Means of age at death according to the grouping in Table 10
MALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (not cancer-related) Years	Age at death (according to death certificate) Years
1998	6	60.0	56.7	66.6	62.0
1999	4	65.0	63.7	68.8	66.8
2000	15	69.3	68.9	71.1	67.8
2001	12	64.3	58.4	75.9	63.6
2002	14	80.2	82.8	77.7	78.6
2003	14	70.4	68.0	76.4	68.4
2004	16	72.0	69.5	76.1	67.8
2005	14	65.9	64.4	74.8	65.0
2006	16	74.1	70.3	85.4	69.0
2007	14	73.7	73.5	74.1	73.2
2008	17	66.9	66.0	80.5	66.2
2009	16	70.4	66.8	78.3	69.4
2010	14	73.3	68.9	84.4	70.1
2011	16	73.8	74.5	72.2	73.2
2012	22	69.0	64.5	78.7	65.4
1998-2012	210	70.6	68.1	76.9	68.5

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11b

Means of age at death according to the grouping in Table 10
FEMALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (not cancer-related) Years	Age at death (according to death certificate) Years
1998	6	81.2	74.0	88.4	82.8
1999	5	72.1	60.0	80.2	71.0
2000	5	68.1	68.1		73.2
2001	4	78.0	78.0		78.0
2002	6	75.7	78.7	72.6	75.2
2003	10	78.8	74.4	88.9	74.4
2004	5	74.4	76.2	73.1	76.2
2005	11	73.0	71.9	77.7	71.9
2006	13	80.5	79.1	97.1	80.5
2007	8	71.6	67.3	101.6	67.3
2008	8	76.1	79.5	74.0	81.1
2009	6	80.8	80.8		80.8
2010	13	73.6	74.8	71.7	72.6
2011	12	65.8	62.1	84.7	62.6
2012	8	84.6	77.7	91.5	79.6
1998-2012	120	75.4	73.2	80.8	74.4

By 2010, life expectancy for a newborn male in Germany is 77.5 years compared with 82.6 years for his female counterpart.

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 12a

Mortality measures (cancer-related death) and mortality-incidence-index
by year of death
MALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	4	0.4	0.27	0.3	0.35	0.4	0.29	0.4	0.25
1999	3	0.3	0.27	0.1	0.24	0.2	0.27	0.2	0.27
2000	12	1.1	0.80	0.6	0.75	0.9	0.79	1.2	0.81
2001	8	0.7	1.00	0.4	1.00	0.6	0.90	0.8	0.95
2002	7	0.4	0.50	0.2	0.41	0.3	0.52	0.5	0.62
2003	10	0.5	0.45	0.3	0.43	0.5	0.47	0.6	0.48
2004	10	0.5	0.67	0.3	0.58	0.4	0.61	0.6	0.65
2005	12	0.6	0.60	0.3	0.59	0.5	0.59	0.7	0.64
2006	12	0.6	0.57	0.3	0.43	0.5	0.48	0.6	0.58
2007	10	0.5	0.33	0.2	0.26	0.3	0.30	0.5	0.37
2008	16	0.7	0.57	0.4	0.52	0.6	0.60	0.7	0.66
2009	11	0.5	0.42	0.3	0.35	0.4	0.39	0.5	0.41
2010	10	0.4	0.29	0.2	0.22	0.3	0.26	0.4	0.31
2011	11	0.5	0.33	0.2	0.26	0.3	0.31	0.5	0.35
2012	15	0.7	0.83	0.3	0.68	0.5	0.73	0.6	0.88
1998-2012	151	0.6	0.49	0.3	0.43	0.4	0.47	0.6	0.52

Table 12b

Mortality measures (cancer-related death) and mortality-incidence-index
by year of death
FEMALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	3	0.3	0.50	0.1	0.42	0.2	0.45	0.2	0.53
1999	2	0.2	0.29	0.1	0.61	0.2	0.49	0.2	0.30
2000	5	0.4	1.00	0.2	0.99	0.3	0.98	0.4	1.32
2001	4	0.3	0.80	0.1	0.76	0.2	0.80	0.2	0.71
2002	3	0.2	0.27	0.1	0.18	0.1	0.21	0.1	0.20
2003	7	0.4	0.47	0.1	0.35	0.2	0.42	0.3	0.42
2004	2	0.1	0.25	0.0	0.19	0.1	0.20	0.1	0.18
2005	9	0.5	0.82	0.2	1.18	0.3	1.00	0.4	0.91
2006	12	0.6	0.67	0.2	0.38	0.3	0.48	0.5	0.59
2007	7	0.3	0.50	0.2	0.53	0.2	0.54	0.3	0.52
2008	3	0.1	0.25	0.0	0.13	0.1	0.16	0.1	0.22
2009	6	0.3	0.33	0.1	0.20	0.1	0.22	0.2	0.26
2010	8	0.3	0.47	0.1	0.45	0.2	0.43	0.2	0.45
2011	10	0.4	0.77	0.3	0.98	0.3	0.81	0.4	0.73
2012	4	0.2	0.22	0.1	0.14	0.1	0.17	0.1	0.19
1998-2012	85	0.3	0.48	0.1	0.41	0.2	0.43	0.2	0.45

Table 13

Age distribution of age at death (cancer-related) for period 1998-2012
(**incl. multiple primaries**)

Age at death	Cases			Males			Females		
Years	n	%	Cum.%	n	%	Cum.%	n	%	Cum.%
15-19	1	0.4	0.4		0.0		1	1.2	1.2
20-24	2	0.8	1.3	2	1.3	1.3			1.2
25-29	2	0.8	2.1	1	0.7	2.0	1	1.2	2.4
30-34	1	0.4	2.5	1	0.7	2.6			2.4
35-39	4	1.7	4.2	4	2.6	5.2			2.4
40-44	6	2.5	6.7	5	3.3	8.5	1	1.2	3.5
45-49	8	3.4	10.1	5	3.3	11.8	3	3.5	7.1
50-54	15	6.3	16.4	10	6.5	18.3	5	5.9	12.9
55-59	17	7.1	23.5	14	9.2	27.5	3	3.5	16.5
60-64	15	6.3	29.8	10	6.5	34.0	5	5.9	22.4
65-69	33	13.9	43.7	19	12.4	46.4	14	16.5	38.8
70-74	30	12.6	56.3	21	13.7	60.1	9	10.6	49.4
75-79	38	16.0	72.3	27	17.6	77.8	11	12.9	62.4
80-84	37	15.5	87.8	23	15.0	92.8	14	16.5	78.8
85+	29	12.2	100.0	11	7.2	100.0	18	21.2	100.0
All ages	238	100.0		153	100.0		85	100.0	

Included in the statistics are 39.0% multiple primaries in males and 36.2% in females.

Table 14

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2012
(**incl. multiple primaries**)

Age at death Years	Males n	Females n	Males Age-spec. mortal.	MI-index	Females Age-spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19		1	0.0		0.1	1.00		2.9
20-24	2		0.1	1.00	0.0		2.4	
25-29	1	1	0.1	1.00	0.1	1.00	1.0	0.9
30-34	1		0.0	0.25	0.0		0.6	
35-39	4		0.2	0.25	0.0		1.0	
40-44	5	1	0.2	0.24	0.0	0.20	0.6	0.1
45-49	5	3	0.2	0.26	0.1	0.23	0.3	0.2
50-54	10	5	0.5	0.38	0.3	0.50	0.3	0.2
55-59	14	3	0.8	0.47	0.2	0.18	0.3	0.1
60-64	10	5	0.6	0.26	0.3	0.33	0.1	0.1
65-69	19	14	1.3	0.54	0.9	0.64	0.2	0.2
70-74	21	9	1.8	0.51	0.7	0.45	0.2	0.1
75-79	27	11	3.6	0.73	1.0	0.39	0.2	0.1
80-84	23	14	5.1	1.05	1.6	0.70	0.2	0.1
85+	11	18	3.5	0.85	2.2	0.78	0.1	0.1
All ages	153	85					0.2	0.1
Mortality								
Raw			0.6	0.49	0.3	0.48		
WS			0.3	0.43	0.1	0.41		
ES			0.4	0.47	0.2	0.43		
BRD-S			0.6	0.53	0.2	0.45		
PYLL-70								
per 100,000			4.1		1.6			
ES			3.7		1.5			
AYLL-70			14.5		11.7			

The rates underestimate the prognosis if other synchronous cancers are prognostic unfavorable.

Table 15a

Multiple primaries in deaths in period 1998-2012
MALES

Diagnosis		Total n	Total %↓	Pre n	Pre ←%	Syn-chron ±30d n	Syn-chron ±30d ←%	Post n	Post ←%
C00	Lip	1	1.1					1	100.0
C03-C06	Oral cavity	7	7.6	5	71.4			2	28.6
C07-C08	Salivary gland	3	3.3	1	33.3			2	66.7
C09-C10	Oropharynx	3	3.3	1	33.3			2	66.7
C11	Nasopharynx	1	1.1			1	100.0		
C12-C13	Hypopharynx	2	2.2	1	50.0			1	50.0
C15	Oesophagus	2	2.2					2	100.0
C16	Stomach	5	5.4	2	40.0			3	60.0
C18	Colon	4	4.3	1	25.0			3	75.0
C23-C24	Bile	1	1.1					1	100.0
C25	Pancreas	1	1.1					1	100.0
C26	GI cancer	1	1.1					1	100.0
C30	Middle/inner ear	1	1.1					1	100.0
C30-C31	Sinuses	2	2.2					2	100.0
C32	Larynx	6	6.5	6	100.0				
C33-C34	Lung	8	8.7					8	100.0
C43	Malign. melanoma	4	4.3	1	25.0			3	75.0
C44	Skin others	7	7.6	4	57.1			3	42.9
C46,C49	Soft tissue	3	3.3	1	33.3			2	66.7
C50	Breast	1	1.1					1	100.0
C61	Prostate	14	15.2	6	42.9	1	7.1	7	50.0
C67	Bladder	4	4.3	1	25.0			3	75.0
C70-C72	CNS cancer	2	2.2	1	50.0			1	50.0
C76-C79	CUP	2	2.2			1	50.0	1	50.0
C82-C85	NHL	4	4.3	1	25.0			3	75.0
C90	Mult. myeloma	1	1.1	1	100.0				
C91-C96	Leukaemia	2	2.2					2	100.0
All mult. primaries		92	100.0	33	35.9	3	3.3	56	60.9

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

Table 15b

Multiple primaries in deaths in period 1998-2012
FEMALES

Diagnosis		Total n	Total %↓	Pre n	Pre ←%	Syn-chron ±30d n	Syn-chron ±30d ←%	Post n	Post ←%
C00	Lip	1	2.1	1	100.0				
C03-C06	Oral cavity	3	6.3	3	100.0				
C09-C10	Oropharynx	2	4.2	2	100.0				
C11	Nasopharynx	3	6.3	1	33.3			2	66.7
C12-C13	Hypopharynx	1	2.1	1	100.0				
C14	ENT cancer	1	2.1					1	100.0
C16	Stomach	1	2.1					1	100.0
C18	Colon	2	4.2	2	100.0				
C25	Pancreas	2	4.2					2	100.0
C32	Larynx	1	2.1	1	100.0				
C33-C34	Lung	2	4.2					2	100.0
C40-C41	Bone	1	2.1					1	100.0
C43	Malign. melanoma	1	2.1	1	100.0				
C44	Skin others	3	6.3			1	33.3	2	66.7
C50	Breast	10	20.8	8	80.0			2	20.0
C53	Cervix uteri	1	2.1	1	100.0				
C54	Corpus uteri	1	2.1	1	100.0				
C56	Ovary	2	4.2					2	100.0
C67	Bladder	1	2.1					1	100.0
C70-C72	CNS cancer	4	8.3	1	25.0	1	25.0	2	50.0
C82-C85	NHL	1	2.1					1	100.0
C90	Mult. myeloma	1	2.1					1	100.0
C91-C96	Leukaemia	3	6.3	1	33.3			2	66.7
All mult. primaries		48	100.0	24	50.0	2	4.2	22	45.8

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

Table 16

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2012
(**Singular primaries only** *)

Age at death Years	Males n	Females n	Males Age-spec. mortal.	MI-index	Females Age-spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19		1	0.0		0.1	1.00		3.2
20-24	2		0.1	1.00	0.0		2.6	
25-29	1	1	0.1	1.00	0.1	1.00	1.1	1.0
30-34	1		0.0	0.33	0.0		0.6	
35-39	4		0.2	0.25	0.0		1.1	
40-44	5	1	0.2	0.24	0.0	0.25	0.7	0.1
45-49	5	3	0.2	0.28	0.1	0.25	0.3	0.2
50-54	9	5	0.5	0.39	0.3	0.56	0.3	0.2
55-59	14	3	0.8	0.54	0.2	0.21	0.3	0.1
60-64	9	2	0.5	0.26	0.1	0.17	0.1	0.0
65-69	13	10	0.9	0.57	0.6	0.67	0.1	0.2
70-74	15	7	1.3	0.50	0.5	0.41	0.2	0.1
75-79	20	8	2.7	0.77	0.7	0.40	0.2	0.1
80-84	18	10	4.0	1.00	1.2	0.63	0.2	0.1
85+	8	12	2.6	0.89	1.5	0.75	0.1	0.1
All ages	124	63					0.2	0.1
Mortality								
Raw			0.5	0.49	0.2	0.45		
WS			0.2	0.43	0.1	0.40		
ES			0.4	0.47	0.1	0.41		
BRD-S			0.5	0.52	0.2	0.42		
PYLL-70								
per 100,000			4.0		1.4			
ES			3.6		1.4			
AYLL-70			15.7		13.7			

* See corresponding tables with multiple primaries.

Table 17

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2012
(**Single primaries only** *)

Age at death Years	Males n	Females n	Males Age-spec. mortal.	MI-index	Females Age-spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24	2		0.1	1.00	0.0		2.7	
25-29	1	1	0.1	1.00	0.1	1.00	1.2	1.0
30-34	1		0.0	0.33	0.0		0.6	
35-39	4		0.2	0.27	0.0		1.2	
40-44	5		0.2	0.26	0.0		0.7	
45-49	3	3	0.1	0.18	0.1	0.27	0.2	0.2
50-54	8	3	0.4	0.38	0.2	0.33	0.3	0.1
55-59	11	3	0.6	0.52	0.2	0.25	0.3	0.1
60-64	7	2	0.4	0.23	0.1	0.17	0.1	0.0
65-69	9	8	0.6	0.43	0.5	0.53	0.1	0.2
70-74	9	7	0.8	0.32	0.5	0.44	0.1	0.1
75-79	12	7	1.6	0.60	0.6	0.44	0.2	0.1
80-84	13	7	2.9	0.93	0.8	0.64	0.2	0.1
85+	3	8	1.0	0.50	1.0	0.57	0.1	0.1
All ages	88	49					0.2	0.1
Mortality								
Raw			0.3	0.40	0.2	0.40		
WS			0.2	0.36	0.1	0.34		
ES			0.3	0.39	0.1	0.35		
BRD-S			0.3	0.42	0.1	0.38		
PYLL-70								
per 100,000			3.5		1.0			
ES			3.2		0.9			
AYLL-70			16.9		11.8			

* See corresponding tables with multiple primaries.



Figure 18. Distribution of age at death (bars) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).

The difference between age at diagnosis (Table 3) and age at nasal cavity, middle ear, sinuses cancer-related death (see Table 10) should be considered.

Average mortality (world standard population) 2003 - 2008: Males



Average mortality (world standard population) 2003 - 2008: Females



Figure 19a. Map of cancer mortality (world standard population) by county averaged for period 2003 to 2008. According to their individual mortality rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 0.3/100,000 WS N=67, females 0.1/100,000 WS N=37). Since cancer data are not available in some counties until 2007, the local mortality rates were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 1 women died from nasal cavity, middle ear, sinuses cancer. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 0.1/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 0.6/100,000.

Standardized mortality ratio (SMR) 2003 - 2008: Males



Standardized mortality ratio (SMR) 2003 - 2008: Females



Figure 19b. Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual SMR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=67, females N=37). Since cancer data are not available in some counties until 2007, the local SMR values were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 1 women died from nasal cavity, middle ear, sinuses cancer. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 0.95. Though, the value of this parameter may vary with an underlying probability of 99% between 0.00 and 7.05, and is therefore not statistically striking.

Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

1. **All multiple primaries included**

   The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

2. **First singular primary** (no information about other prior or synchronous malignancy)

   The mortality statistic describes the tumor-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

3. **Single primary** (no information about other prior, syn- or metachronous malignancy)

   The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head/neck and lung).

The index from mortality and incidence (Mortality-Incidence ratio, **MI-index**) is a statistic that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MI- index. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

Shortcuts

AYLL-70	Average years of life lost prior to age 70 given a person dies before that age
BRD-S	German standard population
DCO	Death certificate only
EAR	Excess absolute risk = excess cancer cases (O - E) per 10,000 person-years
ES	European standard population (old)
FRG	Federal Republic of Germany
GEKID	Association of Population-based Cancer Registries in Germany (Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)
LCL	Lower confidence limit
MI-index	Ratio between mortality and incidence
MCR	Munich Cancer Registry (Tumorregister München)
PYLL-70	Potential years of life lost prior to age 70 given a person dies before that age
SEER	Surveillance, Epidemiology, and End Results (USA)
SIR	Standardized incidence ratio
SMR	Standardized mortality ratio
UCL	Upper confidence limit
WS	World standard population

Recommended Citation

Munich Cancer Registry. Baseline statistics C30, C31: Nasal cavity, middle ear, sinuses cancer [Internet]. 2014 [updated 2014 Mar 20; cited 2014 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/base/base_C3031E.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables